Myelodysplastic Syndrome Following Treatment of Malignant Melanoma with Vincristine, ACNU, and Dacarbazine.

Accession number;00A0339669
Title;Myelodysplastic Syndrome Following Treatment of Malignant Melanoma with Vincristine, ACNU, and Dacarbazine.
Author; KAGESHITA T (Kumamoto Univ. School Of Medicine, Kumamoto, Jpn) KURIBAYASHI N (Kumamoto Univ. School Of Medicine, Kumamoto, Jpn) ONO T (Kumamoto Univ. School Of Medicine, Kumamoto, Jpn)
Journal Title;J Dermatol
Journal Code:Z0757A
ISSN:0385-2407
VOL.27;NO.3;PAGE.178-180(2000)
Figure&Table&Reference;FIG.2, REF.10
Pub. Country;Japan
Language;English
Abstract;Therapy-related myelodysplastic syndrome is a rare adverse effect in melanoma patients elicited by chemotherapy. We report a case of myelodysplastic syndrome following treatment of malignant melanoma with alkylating agents. Peripheral blood showed a remarkable suppression of three cell lineages, and the bone marrow was slightly hypercellular. However, no morphological abnormalities were detected in the peripheral blood or the bone marrow, and chromosomal analysis was normal. (author abst.)
FULLTEXT